Abstract
With oral mucosal transudate and serum samples from 101 human immunodeficiency virus type 1 (HIV-1)-infected subjects and 100 HIV-1-negative volunteers, the OraQuick HIV-1 test demonstrated 100% specificity and 96% sensitivity. Four false-negative subjects, who were characterized by early initiation of effective antiretroviral therapy, demonstrated waning serum anti-gp41 titers and Western blot band intensities.
Publication types
-
Comparative Study
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Adult
-
Antiretroviral Therapy, Highly Active
-
Blotting, Western
-
Case-Control Studies
-
False Negative Reactions
-
Female
-
HIV Antibodies / analysis*
-
HIV Antibodies / blood
-
HIV Envelope Protein gp41 / immunology
-
HIV Infections / diagnosis*
-
HIV Infections / drug therapy
-
HIV Infections / immunology
-
HIV-1 / immunology*
-
Humans
-
Immunoassay / methods*
-
Immunoassay / statistics & numerical data
-
Male
-
Middle Aged
-
Mouth Mucosa / immunology
-
Sensitivity and Specificity
Substances
-
HIV Antibodies
-
HIV Envelope Protein gp41